174 related articles for article (PubMed ID: 38092371)
21. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
[TBL] [Abstract][Full Text] [Related]
22. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
[TBL] [Abstract][Full Text] [Related]
23. The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.
Zimling ZG; Jørgensen A; Santoni-Rugiu E
Histopathology; 2012 May; 60(6B):E96-105. PubMed ID: 22394205
[TBL] [Abstract][Full Text] [Related]
24. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
25. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
[TBL] [Abstract][Full Text] [Related]
26. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
[No Abstract] [Full Text] [Related]
27. Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology.
Girolami I; Lucenteforte E; Eccher A; Marletta S; Brunelli M; Graziano P; Pisapia P; Malapelle U; Troncone G; Scarpa A; Huang T; Pantanowitz L
Cancer Cytopathol; 2022 Feb; 130(2):96-109. PubMed ID: 34478240
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
29. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
[TBL] [Abstract][Full Text] [Related]
30. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
31. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.
Hiroshima K; Wu D; Hamakawa S; Tsuruoka S; Ozaki D; Orikasa H; Hasegawa M; Koh E; Sekine Y; Yonemori Y; Nabeshima K; Tsuji S; Miyagi Y; Imai K
Diagn Cytopathol; 2021 May; 49(5):622-632. PubMed ID: 32441895
[TBL] [Abstract][Full Text] [Related]
32. Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations.
Nabeshima K; Hamasaki M; Kinoshita Y; Matsumoto S; Sa-Ngiamwibool P
Pathol Int; 2022 Aug; 72(8):389-401. PubMed ID: 35596704
[TBL] [Abstract][Full Text] [Related]
33. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G; Özekinci S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
[TBL] [Abstract][Full Text] [Related]
34. The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
Chou A; Toon CW; Clarkson A; Sheen A; Sioson L; Gill AJ
Histopathology; 2018 Feb; 72(3):509-515. PubMed ID: 28889523
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.
Shinozaki-Ushiku A; Ushiku T; Morita S; Anraku M; Nakajima J; Fukayama M
Histopathology; 2017 Apr; 70(5):722-733. PubMed ID: 27859460
[TBL] [Abstract][Full Text] [Related]
36. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
Cozzi I; Oprescu FA; Rullo E; Ascoli V
Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
38. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature.
Symes E; Tjota M; Cody B; Kindler H; Mitchell O; Witmer H; Turaga K; Mueller J; Krausz T; Husain AN; Li H
Histopathology; 2024 Feb; 84(3):492-506. PubMed ID: 38084880
[TBL] [Abstract][Full Text] [Related]
39. Development of mesothelioma in situ and its progression to invasive disease observed in a patient with uncontrolled pleural effusions for 15 years.
Hidaka K; Takeda T; Kinoshita Y; Nabeshima K; Tamiya S; Yoshikawa Y; Tsujimura T
Pathol Int; 2020 Dec; 70(12):1009-1014. PubMed ID: 32956524
[TBL] [Abstract][Full Text] [Related]
40. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]